ATE118818T1 - Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung. - Google Patents

Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.

Info

Publication number
ATE118818T1
ATE118818T1 AT89313391T AT89313391T ATE118818T1 AT E118818 T1 ATE118818 T1 AT E118818T1 AT 89313391 T AT89313391 T AT 89313391T AT 89313391 T AT89313391 T AT 89313391T AT E118818 T1 ATE118818 T1 AT E118818T1
Authority
AT
Austria
Prior art keywords
synthetic oligonucleotides
dna
bind
duplex
duplex dna
Prior art date
Application number
AT89313391T
Other languages
English (en)
Inventor
Michael Edward Hogan
Donald Joseph Kessler
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE118818T1 publication Critical patent/ATE118818T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01034—Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
AT89313391T 1988-12-20 1989-12-20 Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung. ATE118818T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28735988A 1988-12-20 1988-12-20

Publications (1)

Publication Number Publication Date
ATE118818T1 true ATE118818T1 (de) 1995-03-15

Family

ID=23102554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89313391T ATE118818T1 (de) 1988-12-20 1989-12-20 Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.

Country Status (10)

Country Link
EP (2) EP0449972A4 (de)
JP (1) JPH04502407A (de)
AT (1) ATE118818T1 (de)
AU (1) AU640910B2 (de)
CA (1) CA2006008C (de)
DE (1) DE68921315T2 (de)
DK (1) DK120091A (de)
ES (1) ES2069598T3 (de)
PT (1) PT92640B (de)
WO (1) WO1990006934A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928863A (en) * 1986-11-26 1999-07-27 Princeton University Triple-stranded nucleic acids
US5422251A (en) * 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5849482A (en) * 1988-09-28 1998-12-15 Epoch Pharmaceuticals, Inc. Crosslinking oligonucleotides
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) * 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
EP0531436A4 (en) * 1990-05-25 1993-06-16 Gilead Sciences, Inc. Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna
EP0463712A3 (en) * 1990-06-27 1992-04-08 University Patents, Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
US5734022A (en) * 1990-08-01 1998-03-31 The Johns Hopkins University Antibodies to a novel mammalian protein associated with uncontrolled cell division
WO1992009705A1 (en) * 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
EP0566670A4 (en) * 1990-12-17 1993-12-08 Idexx Laboratories, Inc. Nucleic acid sequence detection by triple helix formation
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
JPH06510203A (ja) * 1991-08-30 1994-11-17 ザ・ジョーンズ・ホプキンス・ユニバーシティ プリン塩基類似体を含むヌクレオシドオリゴマーを用いる二重鎖ｄｎａの三重らせん複合体の形成
IL103311A0 (en) * 1991-10-07 1993-03-15 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
WO1993009127A1 (en) * 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
JP3739785B2 (ja) * 1991-11-26 2006-01-25 アイシス ファーマシューティカルズ，インコーポレイティド 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
US5616461A (en) * 1992-05-14 1997-04-01 Dana-Farber Cancer Institute Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein
US6403302B1 (en) 1992-09-17 2002-06-11 California Institute Of Technology Methods and compositions for triple helix formation
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
CA2148687A1 (en) * 1992-11-09 1994-05-26 Darwin Prockop Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
EP0674707A4 (de) * 1992-12-04 1998-01-14 Apollon Inc Verbindungen und methoden zur behandlung von leukämien.
JPH08504103A (ja) * 1992-12-08 1996-05-07 ジンタ・インコーポレイテッド 新しいモチーフを用いた３重らせん複合体の形成
AU6296294A (en) 1993-01-26 1994-08-15 Microprobe Corporation Bifunctional crosslinking oligonucleotides adapted for linking to a desired gene sequence of invading organism or cell
US6323185B1 (en) 1993-04-23 2001-11-27 The United States Of America As Represented By The Department Of Health And Human Services Anti-viral guanosine-rich oligonucleotides and method of treating HIV
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US5567604A (en) 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
WO1995000638A2 (en) 1993-06-23 1995-01-05 Genesys Pharma Inc. Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
JPH09503644A (ja) * 1993-06-25 1997-04-15 エール ユニバーシティ 部位特異的変異誘発のための化学的に修飾されたオリゴヌクレオチド
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
WO1995011253A1 (en) * 1993-10-18 1995-04-27 The Walter And Eliza Hall Institute Of Medical Research A method for enhancing neurone survival and agents useful for same
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5492899A (en) * 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
US6136858A (en) 1994-01-10 2000-10-24 Abbott Laboratories Infant formula and methods of improving infant stool patterns
US5488039A (en) * 1994-01-10 1996-01-30 Abbott Laboratories Method for the production of an enteral formula containing ribo-nucleotides
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
US5808037A (en) * 1995-09-15 1998-09-15 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6156513A (en) * 1995-09-15 2000-12-05 Ramareddy V. Guntaka Oligmers which inhibit expression of collagen genes
FR2746412B1 (fr) * 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa Purification d'adn plasmidique de qualite pharmaceutique
US6312925B1 (en) 1997-05-08 2001-11-06 Epoch Pharmaceuticals, Inc. Methods and compositions to facilitate D-loop formation by oligonucleotides
US6930175B1 (en) 1997-12-12 2005-08-16 The Johns Hopkins University School Of Medicine Gene family with transformation modulating activity
JP2002541264A (ja) * 1999-04-08 2002-12-03 ユーエイビー・リサーチ・ファウンデーション 冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
FR2822156A1 (fr) * 2001-03-16 2002-09-20 Centre Nat Rech Scient Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications
US8129514B2 (en) 2003-06-19 2012-03-06 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
WO2004111183A2 (en) 2003-06-19 2004-12-23 Evogene Ltd. Plant trichome-specific promoter and leucoplast signal sequence
CN101273130B (zh) 2005-07-07 2012-05-30 耶路撒冷希伯来大学伊森姆研究发展公司 用于下调h19的核酸物质及其使用方法
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2008087641A2 (en) 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
CA2696833A1 (en) 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
EP2543389A3 (de) 2007-08-02 2013-04-24 Gilead Biologics, Inc. Verfahren und Zusammensetzungen zur Behandlung und Diagnose von Fibrose, Tumorinvasion, Angiogenese und Metastasen
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
CN102037144B (zh) 2008-04-01 2013-09-25 生物检索技术股份有限公司 稳定化的核酸暗猝灭剂-荧光团探针
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
KR20120063488A (ko) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. 리실 옥시다제 및 ｌｏｘｌ２로부터의 촉매 도메인
US20120157512A1 (en) 2009-08-21 2012-06-21 Monsanto Technology Llc Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
EP2475381A2 (de) 2009-09-08 2012-07-18 Yeda Research and Development Co. Ltd. Verfahren zur mobilisierung eines hämatopoetischen vorläufers
US20120171213A1 (en) 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
CN102906263B (zh) 2009-10-14 2017-05-31 耶路撒冷希伯来大学伊森姆研究发展公司 用于控制蜂中的瓦螨的组合物
AU2011212830B2 (en) 2010-02-04 2014-05-22 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
IN2012MN02247A (de) 2010-04-18 2015-06-12 Yeda Res & Dev
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9187787B2 (en) 2010-06-16 2015-11-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of diagnosing and treating cancer
CN103210082A (zh) 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
EP2627766B1 (de) 2010-10-17 2016-05-25 Yeda Research and Development Co. Ltd. Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen
EP2720720B1 (de) 2011-06-14 2018-02-28 Yeda Research and Development Co. Ltd. Kombinationstherapie zur verhinderung von dcis-bildung und deren fortschreiten zu brustkrebs
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
US9617331B2 (en) 2011-11-27 2017-04-11 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide
EP3401394A1 (de) 2012-02-22 2018-11-14 Exostem Biotec Ltd Erzeugung von neuralen stammzellen
RU2015149680A (ru) 2013-04-21 2017-05-24 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
BR112016000555B1 (pt) 2013-07-19 2022-12-27 Monsanto Technology Llc Método para controlar uma infestação da espécie de leptinotarsa em uma planta, composição inseticida e construção de dna recombinante
AR098295A1 (es) 2013-11-04 2016-05-26 Monsanto Technology Llc Composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
BR112016022711A2 (pt) 2014-04-01 2017-10-31 Monsanto Technology Llc composições e métodos para controle de pragas de inseto
US10378012B2 (en) 2014-07-29 2019-08-13 Monsanto Technology Llc Compositions and methods for controlling insect pests
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
EP3220945A2 (de) 2014-11-17 2017-09-27 Yeda Research and Development Co., Ltd. Verfahren zur behandlung von krankheiten im zusammenhang mit der mitochondrienfunktion
PL3256589T3 (pl) 2015-01-22 2022-02-21 Monsanto Technology Llc Kompozycje i sposoby kontrolowania leptinotarsa
EP3261582B1 (de) 2015-02-26 2021-01-06 Remodeless CV Ltd. Verfahren und zusammensetzungen in zusammenhang mit leptin-antagonisten
WO2016135732A1 (en) 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth
CA2984907A1 (en) 2015-05-04 2016-11-10 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
EP3294280A1 (de) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrinhemmer zur behandlung von krebs
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
CN107847531A (zh) 2015-05-21 2018-03-27 耶达研究及发展有限公司 用于促进健康的细菌群
US11053495B2 (en) 2015-07-17 2021-07-06 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
EP3331546B1 (de) 2015-08-03 2023-10-04 Biokine Therapeutics Ltd. Cxcr4-antagonist zur behandlung von krebs
EP3373939A4 (de) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
US10828318B2 (en) 2016-01-06 2020-11-10 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
US11555192B2 (en) 2017-07-27 2023-01-17 The National Institute for Biotechnology in the Negev Ltd. SMAC/Diablo inhibitors useful for treating cancer
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
EP3723785A1 (de) 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Komplexe modulatoren des cop9-signalosoms (csn) und deren verwendung
WO2019155465A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
IL314908A (en) 2018-03-29 2024-10-01 Technion Res & Dev Foundation Bubbles containing PTEN inhibitor and their uses
KR20210018267A (ko) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 간외 전달
EP3927378A1 (de) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Verfahren zur reduktion von arzneimittelinduzierter nephrotoxizität
AU2020279101A1 (en) 2019-05-17 2021-11-18 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
CA3147575A1 (en) 2019-07-29 2021-02-04 Yeda Research And Development Co. Ltd. Methods of treating and diagnosing lung cancer
WO2022011214A1 (en) 2020-07-10 2022-01-13 Alnylam Pharmaceuticals, Inc. Circular sirnas
JP2024527584A (ja) 2021-07-09 2024-07-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
US20240358828A1 (en) 2021-08-10 2024-10-31 Gamida Cell Ltd. Engineered nk cells, methods of their production and uses thereof
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024137756A1 (en) * 2022-12-23 2024-06-27 Hongene Biotech Corporation Compounds and methods for liquid phase oligonucleotide synthesis

Also Published As

Publication number Publication date
WO1990006934A1 (en) 1990-06-28
AU4838490A (en) 1990-07-10
CA2006008C (en) 2000-02-15
EP0449972A4 (en) 1992-03-18
PT92640A (pt) 1990-06-29
DE68921315D1 (de) 1995-03-30
JPH04502407A (ja) 1992-05-07
EP0375408A1 (de) 1990-06-27
PT92640B (pt) 1995-09-12
ES2069598T3 (es) 1995-05-16
DK120091D0 (da) 1991-06-20
EP0375408B1 (de) 1995-02-22
AU640910B2 (en) 1993-09-09
DE68921315T2 (de) 1995-08-03
CA2006008A1 (en) 1990-06-20
DK120091A (da) 1991-06-20
EP0449972A1 (de) 1991-10-09

Similar Documents

Publication Publication Date Title
ATE118818T1 (de) Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.
EP0828849A4 (de) Oligonukleotidliganden mit hoher affinität für wachstumsfaktoren
ATE161587T1 (de) Technik des genetischen fingerabdrucks mit dns- vervielfältigung
DE69824716D1 (de) Methode zur sequenzierung von nukleinsäuren
DE69627698D1 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
ATE263237T1 (de) Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung
DK51092D0 (da) Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
DE69615411D1 (de) Verfahren zur Herstellung von Polynucleotiden mit erwünschten Eigenschaften mittels wiederholter Selektion und Rekombination
DE502588T1 (de) Verfahren zur Amplifizierung von Nukleinsäuresequenzen.
ATE106948T1 (de) Verfahren zur amplifizierung von nukleinsäuren.
DE69016826D1 (de) Verfahren zur Synthese von Ribonukleinsäure (RNS).
ATE278807T1 (de) Neue anordnungen von oligonukleotiden und ihr nutzen zum sortieren, isolieren, sequenzierung und manipulieren von nukleinsäuren
DE69233458D1 (de) Nukleinsäuretypisierung durch polymeraseverlängerung von oligonukleotiden unter verwendung von terminator-mischungen
ATE141956T1 (de) Verfahren zur vervielfältigung von nukleinsäuresequenzen
DE69433487D1 (de) Methoden und zusammensetzungen zur effizienten nukleinsaeuresequenzierung
CN105925671A (zh) 一种从核酸样品富集目标序列核酸的方法
EP2390258A8 (de) Polymerasen mit hoher Wiedergabetreue und Verwendungen davon
DE69637041D1 (de) Dna-fragment, dieses enthaltender rekombinanter vektor und verfahren zur expression von fremdgenen unter dessen verwendung
ES2394881T3 (es) Procedimiento basado en la AFLP para la integración de mapas físicos y genéticos
EP0812911B1 (de) Methode zur Bildung makromolekularer Mikrogenpolymeren
DE59608651D1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
DE59410068D1 (de) Verfahren zur spezifischen Klonierung von Nukleinsäuren
DE68910836D1 (de) In vitro mutagenese.
Kumazaki et al. The nucleotide sequences of 5S rRNAs from two ribbon worms: Emplectonema gracile contains two 5S rRNA species differing considerably in their sequences

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties